Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and ...

AC Immune receives a "Buy" rating, driven by positive phase 2 VacSYn trial results for ACI-7104.056 in early Parkinson's ...

Could a new class of oral drugs be game changers?

Hub101 held its 2024 Demo Day for its Idea2Do program where several companies pitched their ideas for startups. Cal Lutheran ...

SOM professor Paul Witman was recently recognized for his years of contributions to the Information Systems Educational ...

Dec 15 (Reuters) - The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's Enhertu in combination with Roche's drug, Perjeta, for the first-line treatment of ...

The biotech’s lead asset, AVD-104, failed to beat Astellas’ Izervay at slowing the rate of retina lesion growth, the primary ...

A catalyst for technology-based economic development in life sciences . In 1984, three of North Carolina’s largest ...

Future Market Insights, Inc. (FMI) is an ESOMAR-certified, ISO 9001:2015 market research and consulting organization, trusted ...